GlassScriptPhysician profile
Mohammad Tahir
NPI 1881608008
$173,477.09
in general payments reported to CMS, 2019-2025
50 companies · $57K in 2025
The $57K reported for 2025 was more than what 99% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $5,091 · 2020: $1,091 · 2021: $4,407 · 2022: $29K · 2023: $22K · 2024: $54K · 2025: $57K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $129K · Food and Beverage: $3,443 · Travel and Lodging: $1,325 · Education: $187.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $128,724.18 |
| Food and Beverage | $3,443.27 |
| Travel and Lodging | $1,325.13 |
| Education | $187.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $159,165.89 | 2021-2025 | |
| Biotronik INC. | $4,049.45 | 2019 | |
| Novartis Pharmaceuticals Corporation | $1,969.93 | 2019-2025 | |
| Medtronic, INC. | $1,390.21 | 2023 | Micra |
| Janssen Pharmaceuticals, INC | $630.11 | 2019-2024 | Xarelto |
| Merck Sharp & Dohme LLC | $485.57 | 2021-2025 | Verquvo, Capvaxive, Winrevair |
| Astrazeneca Pharmaceuticals LP | $471.80 | 2019-2025 | Lokelma, Farxiga, Brilinta |
| Amgen INC. | $431.48 | 2019-2025 | Repatha, Repatha |
| Esperion Therapeutics, INC. | $410.96 | 2020-2025 | Nexletol |
| Novo Nordisk INC | $358.23 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $311.39 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $308.20 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $286.22 | 2019-2024 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $277.70 | 2019-2025 | Lifevest |
| Vifor Pharma, INC. | $244.67 | 2019-2021 |
Show all 46 companies
4 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Tahir listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.